ROLE OF ORAL ZINC IN CHILDREN WITH NEPHROTIC SYNDROME
Not Applicable
- Conditions
- Health Condition 1: N049- Nephrotic syndrome with unspecified morphologic changes
- Registration Number
- CTRI/2021/01/030586
- Lead Sponsor
- REDDY NIKHIL RAJESHWAR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All children between 1 to 12 years of age with diagnosis of steriod sensitive nephrotic syndrome
Exclusion Criteria
secondary Nephrotic syndrome
congenital nephrotic syndrome
steriod resistant nephrotic syndrome
nephritic syndrome
patient who have taken zinc theraphy in last 3 months
age < 1year and > 12year
chronic infection (TB)
severe Iron deficiency anemia
patients whose parent didnt give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Role of zinc supplementation in reduction of relapses in study group as compared to placebo groupTimepoint: June 2022
- Secondary Outcome Measures
Name Time Method Role of zinc in reduction of infection rate , mean growth,cumulative dose of steroid and adverse effects in children with steroid sensitive nephrotic syndromeTimepoint: patients will be evaluated for number of relapses at 1 month, 2 months, 4 months and 6 months of study